Back to Search Start Over

Data from Rapid Development of Hypertension by Sorafenib: Toxicity or Target?

Authors :
Michael B. Atkins
Benjamin D. Humphreys
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes. (Clin Cancer Res 2009;15(19):5947–9)

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....45c735bbec54a845bf2e81163409cdbf

Tools

Authors Abstract Subjects Details